The Marked Chart Wire · Health
Rapport Therapeutics
Rapport Therapeutics phase 2 bipolar study hits main goal
Rapport Therapeutics reported that a mid-stage study of RAP-219 for acute bipolar mania reached its main objective.
More Health news
CRISPR Therapeutics
Crystallizing CRISPR therapeutics' Heart Disease pipeline potential
CRISPR Therapeutics' pipeline candidate CTX310 is viewed as having a larger market opportunity than its approved product Casgevy.
Nubeqa
Orion shares positive Phase III data for prostate drug
Orion Corporation stated that adding Nubeqa to standard care significantly lowered the chance of disease spread or mortality in high-risk patients.
Lung Cancer
Amgen therapy lowers mortality risk in severe lung disease
Amgen reported that adding its medication to AstraZeneca’s immunotherapy reduced the chance of death by 58 percent for individuals with advanced lung tumors.
Cancer Vaccine
Moderna and Merck share final stage data for cancer shot
The two companies disclosed late-stage clinical findings for their mRNA therapy, intismeran autogene, after an information leak occurred.
AbbVie
AbbVie wins FDA nod for injectable Crohn's therapy option
The FDA approved an injectable version of AbbVie's Skyrizi to treat moderate to severe Crohn's disease.
Novartis
Novartis drug meets trial goals for rare childhood cancer
Novartis said its drug remibrutinib met primary endpoints in phase 3 trials for rhabdomyosarcoma. The treatment cut relapse rates by 35 percent compared with a rival therapy, and the company plans to seek global approval.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.